| __timestamp | Celldex Therapeutics, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 21226345 |
| Thursday, January 1, 2015 | 4011000 | 139626 |
| Friday, January 1, 2016 | 102026000 | 93831530 |
| Sunday, January 1, 2017 | 96171000 | 79419009 |
| Monday, January 1, 2018 | 66449000 | 368673 |
| Tuesday, January 1, 2019 | 42672000 | 477121 |
| Wednesday, January 1, 2020 | 42534000 | 1895029 |
| Friday, January 1, 2021 | 3068000 | 8034589 |
| Saturday, January 1, 2022 | 1400000 | 20443000 |
| Sunday, January 1, 2023 | 3008000 | 33745000 |
Infusing magic into the data realm
In the competitive world of biotechnology, cost efficiency can be a decisive factor for success. This analysis compares the cost of revenue efficiency between Intra-Cellular Therapies, Inc. and Celldex Therapeutics, Inc. over the past decade. From 2014 to 2023, Celldex Therapeutics experienced a significant fluctuation in its cost of revenue, peaking in 2014 and 2016 with over $100 million, before dropping to just $3 million in 2023. In contrast, Intra-Cellular Therapies showed a more consistent upward trend, starting at $21 million in 2014 and reaching $33 million by 2023. This suggests a strategic shift towards more efficient revenue management. The data highlights the importance of cost control in sustaining growth and competitiveness in the biotech sector. As these companies continue to innovate, their financial strategies will be crucial in determining their market position.
Cost Insights: Breaking Down AbbVie Inc. and Intra-Cellular Therapies, Inc.'s Expenses
Cost of Revenue Trends: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Amgen Inc. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Grifols, S.A.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: MorphoSys AG vs Celldex Therapeutics, Inc.